Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Fitzpatrick

Showing results (41-50 of 171) with videos related to

Pageof 18
Sort By:
BJU International|August 14, 2012
Rising to the challengeRoger S Kirby, John M Fitzpatrick
BJU International|November 28, 2008
Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence?Roger S Kirby, John M Fitzpatrick
Postgraduate Medical Journal|February 20, 2007
Medical treatment of benign prostatic hyperplasiaStephen S Connolly, John M Fitzpatrick
Current Opinion in Urology|July 7, 2011
BMI and the risk of renal cell carcinomaBarry B McGuire, John M Fitzpatrick
BJU International|August 5, 2004
The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasiaGlenn S Gerber, John M Fitzpatrick
BJU International|July 27, 2005
How should we advise patients about the chemoprevention of prostate cancer?Roger S Kirby, John M Fitzpatrick
BJU International|March 2, 2006
Management of acute urinary retentionJohn M Fitzpatrick, Roger S Kirby
BJU International|March 7, 2008
FingerTip Urology: illustrations for patient dialogue at the click of your cursorR A Gardiner, John M Fitzpatrick
BJU International|June 21, 2012
Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)A Oliver Sartor, John M Fitzpatrick
BJU International|October 18, 2005
Radical prostatectomy vs watchful waitingRoger S Kirby, John M Fitzpatrick
Pageof 18

Showing results (41-50 of 171) with videos related to

Sort By:
Pageof 18
BJU International|August 14, 2012
Rising to the challengeRoger S Kirby, John M Fitzpatrick
BJU International|November 28, 2008
Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence?Roger S Kirby, John M Fitzpatrick
Postgraduate Medical Journal|February 20, 2007
Medical treatment of benign prostatic hyperplasiaStephen S Connolly, John M Fitzpatrick
Current Opinion in Urology|July 7, 2011
BMI and the risk of renal cell carcinomaBarry B McGuire, John M Fitzpatrick
BJU International|August 5, 2004
The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasiaGlenn S Gerber, John M Fitzpatrick
BJU International|July 27, 2005
How should we advise patients about the chemoprevention of prostate cancer?Roger S Kirby, John M Fitzpatrick
BJU International|March 2, 2006
Management of acute urinary retentionJohn M Fitzpatrick, Roger S Kirby
BJU International|March 7, 2008
FingerTip Urology: illustrations for patient dialogue at the click of your cursorR A Gardiner, John M Fitzpatrick
BJU International|June 21, 2012
Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)A Oliver Sartor, John M Fitzpatrick
BJU International|October 18, 2005
Radical prostatectomy vs watchful waitingRoger S Kirby, John M Fitzpatrick
Pageof 18